Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GCVRZ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GCVRZMario Gabelli 2015-06-30 Reduce$0.63 - $0.75
($0.69)
$ 0.20-71%Reduce 3.13%72,100
GCVRZMario Gabelli 2015-03-31 Reduce$0.6 - $0.81
($0.7)
$ 0.20-71%Reduce 58.50%74,431
GCVRZMario Gabelli 2014-12-31 Reduce$0.47 - $0.87
($0.61)
$ 0.20-67%Reduce 40.88%179,351
GCVRZFirst Eagle Investment 2014-12-31 Reduce$0.47 - $0.87
($0.61)
$ 0.20-67%Reduce 35.34%146,402
GCVRZMichael Price 2014-09-30 Reduce-0.24%$0.45 - $0.51
($0.49)
$ 0.20-59%Reduce 75.83%1,275,000
GCVRZMario Gabelli 2014-09-30 Reduce$0.45 - $0.51
($0.49)
$ 0.20-59%Reduce 45.86%303,351
GCVRZMario Gabelli 2014-03-31 Reduce$0.3 - $0.47
($0.37)
$ 0.20-46%Reduce 35.10%631,351
GCVRZMichael Price 2013-12-31 Add0.06%$0.32 - $2.04
($1.21)
$ 0.20-83%Add 31.68%5,300,000
GCVRZFirst Eagle Investment 2013-12-31 Add$0.32 - $2.04
($1.21)
$ 0.20-83%Add 16262.50%229,402
GCVRZWhitney Tilson 2013-09-30 Add0.1%$1.82 - $2.04
($1.9)
$ 0.20-89%Add 62.20%81,100
GCVRZMichael Price 2012-03-31 Add0.19%$1.25 - $1.37
($1.22)
$ 0.20-84%Add 29.41%4,400,000
GCVRZFirst Eagle Investment 2011-12-31 Reduce$0.89 - $1.34
($1.12)
$ 0.20-82%Reduce 99.53%1,402
GCVRZMichael Price 2011-09-30 Add0.26%$0.99 - $2.56
($1.4)
$ 0.20-86%Add 70.00%3,400,000
GCVRZFirst Eagle Investment 2011-09-30 Reduce-0.01%$0.99 - $2.56
($1.4)
$ 0.20-86%Reduce 81.30%301,402
GCVRZMichael Price 2011-06-30 Buy 0.7%$2.29 - $2.63
($2.44)
$ 0.20-92%New holding2,000,000
GCVRZMario Gabelli 2011-06-30 Buy 0.04%$2.29 - $2.63
($2.44)
$ 0.20-92%New holding2,288,150
GCVRZFirst Eagle Investment 2011-06-30 Buy 0.02%$2.29 - $2.63
($2.44)
$ 0.20-92%New holding1,611,585
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GCVRZ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GCVRZ: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about GCVRZ:

    News about GCVRZ:

    Articles On GuruFocus.com

    More From Other Websites
    European heart experts okay longer use of blood thinners Aug 29 2015
    European Factors-Stocks set to end rollercoaster week with gains Aug 28 2015
    Shire bid for Baxalta highlights orphan drug's appeal Aug 06 2015
    Europe close: Stocks rebound following China selloff Jul 28 2015
    AstraZeneca sells rare cancer drug to Sanofi for up to $300 mln Jul 27 2015
    AstraZeneca sells rare cancer drug to Sanofi for up $300 mln Jul 27 2015
    Europe close: Stocks rise on Greek bailout agreement Jul 13 2015
    Global pharma firms grilled about tax in Australia Jul 02 2015
    Drugmakers warn Greek medicine supply "may be in jeopardy" Jun 29 2015
    PureTech raises $171 million in latest London health listing Jun 19 2015
    New drug compound may beat malaria with single $1 dose Jun 17 2015
    Woodford exits bets on Sanofi, adds drug, tech firms Jun 11 2015
    Cholesterol drug wars Jun 09 2015
    FDA to make ruling on new cholesterol drugs Jun 09 2015
    FDA panel backs cholesterol drug Jun 09 2015
    PureTech looks to raise $160m with London listing May 26 2015
    Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
    Hedge fund firm Man Group feels investor backlash on pay May 08 2015
    Heart drugs take center stage Mar 16 2015
    Long-term use of AstraZeneca heart drug brings benefits, some risks Mar 14 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK